Search

Subject Muscles

263. Cancer cachexia causes skeletal muscle damage via transient receptor potential vanilloid 2‐independent mechanisms, unlike muscular dystrophy. Issue 3 (19th November 2015)

Authors:
Iwata, Yuko; Suzuki, Nobuyuki; Ohtake, Hitomi; Kamauchi, Shinya; Hashimoto, Naohiro; Kiyono, Tohru; Wakabayashi, Shigeo
Journal:
Journal of cachexia, sarcopenia and muscle
Issue:
Volume 7:Issue 3(2016)
Page Start:
366
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

265. Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo‐controlled, international multicentre phase II study (the ACT‐ONE trial). Issue 3 (1st July 2016)

Authors:
Stewart Coats, Andrew J.; Ho, Gwo Fuang; Prabhash, Kumar; von Haehling, Stephan; Tilson, Julia; Brown, Richard; Beadle, John; Anker, Stefan D.
Journal:
Journal of cachexia, sarcopenia and muscle
Issue:
Volume 7:Issue 3(2016)
Page Start:
355
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

266. Increased expression of H19/miR‐675 is associated with a low fat‐free mass index in patients with COPD. Issue 3 (5th January 2016)

Authors:
Lewis, Amy; Lee, Jen Y.; Donaldson, Anna V.; Natanek, S. Amanda; Vaidyanathan, Srividya; Man, William D.‐C.; Hopkinson, Nicholas S.; Sayer, Avan A.; Patel, Harnish P.; Cooper, Cyrus; Syddall, Holly; Polkey, Michael I.; Kemp, Paul R.
Journal:
Journal of cachexia, sarcopenia and muscle
Issue:
Volume 7:Issue 3(2016)
Page Start:
330
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗